InsiderTrades

Form 4 for KLRA Kailera Therapeutics, Inc.

Accepted 2026-04-20 18:00:25 ET · period of report 2026-04-16 · accession 0001193125-26-164388 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2026-04-20 18:00 2026-04-20 KLRA Kaplan Andrew T. Dir, 10% C - Cnv Deriv — +17.86M 17.86M New —
DI 2026-04-20 18:00 2026-04-20 KLRA Kaplan Andrew T. Dir, 10% P - Purchase $16.00 +8.40M 26.26M +47% +$134.38M
DI 2026-04-20 18:00 2026-04-20 KLRA Kaplan Andrew T. Dir, 10% C - Cnv Deriv $0.00 -17.86M 0 -100% $0
D 2026-04-20 18:00 2026-04-16 KLRA Kaplan Andrew T. Dir, 10% A - Grant $0.00 +38.3K 38.3K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-04-20 C A 17,857,143 — 17,857,143 I See footnotes — — (F1) Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. (F3) Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). (F4) Mr. Kaplan is a Partner of Bain Capital Investors, LLC ("BCI"). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
2 Common Common Stock 2026-04-20 P A 8,398,438 $16.00 26,255,581 I See footnotes — — (F3) Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). (F4) Mr. Kaplan is a Partner of Bain Capital Investors, LLC ("BCI"). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
3 Derivative Series B Preferred Stock 2026-04-20 C D 17,857,143 $0.00 0 I See footnotes — · — to — 17,857,143 Common Stock (F1) Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. (F1) Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. (F1) Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. (F3) Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). (F4) Mr. Kaplan is a Partner of Bain Capital Investors, LLC ("BCI"). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
4 Derivative Stock Option (right to buy) 2026-04-16 A A 38,300 $0.00 38,300 D $16.00 · — to 2036-04-16 38,300 Common Stock (F2) The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to Mr. Kaplan's continued service through each such vesting date.